Cellecta

Presentation: Loss-of-Function Genetic Screens with RNAi and CRISPR Libraries

Cellecta Presentations

Tumor microenvironment is the current focus in cancer. Immune infiltrate in several human carcinoma types is implicated in prognosis and/or response to therapy. Molecular profiles of tumors and tumor-associated cells hold considerable promise as biomarkers of clinical outcomes. Considering each of these, Cellecta developed a novel Driver-Map portfolio—a targeted expression profiling service that leverages the power of Multiplex PCR and NGS assays and allows you to obtain transcriptome analysis of your sample. It can be used to detect cellular composition, profile immunotherapy targets and, obtain expression analysis of ~8,000 genes. Join us for this webinar to learn about technology validation and intended applications.

Cellecta Webinar on Driver-Map Targeted Gene Expression, June 2016 - CHI (Cambridge Healthtech)

Loss-of-function genetic screens with pooled sgRNA and shRNA libraries aid in discovery / prioritization of drug targets, understanding of disease progression and gene-disease associations, analysis of signal transduction pathways, characterization of the mechanisms for compounds, uncovering of synergistic gene interactions, and identification of markers of drug resistance and sensitivity. This webinar presents a comparison of loss-of-function genetic screens performed with CRISPR versus RNAi technology.

Cellecta

Home

Videos

Playlists

About

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.